Multiple Myeloma (MM) is the second most common hematological malignancy that originates from plasma cells. Over the last 20 years, treatment for patients of MM has advanced significantly; but despite ...
Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study. Background: MGD009 is a B7-H3 x CD3 ...
Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies Targeting prostate-specific ...
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback